Fluclotizolam

Fluclotizolam

Legal status
Legal status	CA: Schedule IV DE: NpSG (Industrial and scientific use only) UK: Under Psychoactive Substances Act
Identifiers
IUPAC name 2-chloro-4-(2-fluorophenyl)-9-methyl-4H-thieno[3,2-f] [1,2,4]triazolo[4,3-a] [1,4]diazepine
CAS Number	54123-15-8
PubChem CID	21317700
ChemSpider	15332007
UNII	4Z9Y7GEG8Z
CompTox Dashboard (EPA)	DTXSID601336484
Chemical and physical data
Formula	C15H10ClFN4S
Molar mass	332.78 g·mol^−1
3D model (JSmol)	Interactive image
SMILES Fc4ccccc4C2=NCc1nnc(C)n1c3sc(Cl)cc23
InChI InChI=1S/C15H10ClFN4S/c1-8-19-20-13-7-18-14(9-4-2-3-5-11(9)17)10-6-12(16)22-15(10)21(8)13/h2-6H,7H2,1H3 Key:ZDYRCUZZLRLMHG-UHFFFAOYSA-N

Fluclotizolam is a thienotriazolodiazepine derivative which was first synthesised in 1979,^[1] but was never marketed. It has subsequently been sold as a designer drug, first being definitively identified in 2017.^{[2][3][4][5][6][7]}

See also

• Brotizolam
• Clotizolam
• Deschloroclotizolam
• Etizolam
• Flualprazolam
• Fluadinazolam
• Flubrotizolam
• Fluetizolam
• Ro09-9212

References

1. US 4155913, Hellerbach J, Zeller P, Binder D, Hromatka O, "Thienotriazolodiazepine derivatives.", issued 22 May 1979, assigned to Hoffmann La Roche Inc 
2. Zawilska JB, Wojcieszak J (July 2019). "An expanding world of new psychoactive substances-designer benzodiazepines". Neurotoxicology. 73: 8–16. doi:10.1016/j.neuro.2019.02.015. PMID 30802466. S2CID 73461430.
3. Moosmann B, Auwärter V (2018). "Designer Benzodiazepines: Another Class of New Psychoactive Substances.". In Maurer H, Brandt S (eds.). New Psychoactive Substances. Handbook of Experimental Pharmacology. Vol. 252. pp. 383–410. doi:10.1007/164_2018_154. ISBN 978-3-030-10560-0. PMID 30367253.
4. Chetraru E, Ameline A, Gheddar L, Raul JS, Kintz P (February 2018). "Les designer benzodiazepines: qu'en sait-on aujourd'hui?". Toxicologie Analytique et Clinique. 30 (1): 5–18. doi:10.1016/j.toxac.2017.12.001.
5. Orsolini L, Corkery JM, Chiappini S, Guirguis A, Vento A, De Berardis D, et al. (2020). "'New/Designer Benzodiazepines': An Analysis of the Literature and Psychonauts' Trip Reports". Current Neuropharmacology. 18 (9): 809–837. doi:10.2174/1570159X18666200110121333. PMC 7569319. PMID 31933443.
6. Catalani V, Botha M, Corkery JM, Guirguis A, Vento A, Scherbaum N, Schifano F (July 2021). "The Psychonauts' Benzodiazepines; Quantitative Structure-Activity Relationship (QSAR) Analysis and Docking Prediction of Their Biological Activity". Pharmaceuticals. 14 (8): 720. doi:10.3390/ph14080720. PMC 8398354. PMID 34451817.
7. Catalani V, Floresta G, Botha M, Corkery JM, Guirguis A, Vento A, et al. (January 2023). "In silico studies on recreational drugs: 3D quantitative structure activity relationship prediction of classified and de novo designer benzodiazepines". Chemical Biology & Drug Design. 101 (1): 40–51. doi:10.1111/cbdd.14119. hdl:2299/25749. PMID 35838189. S2CID 250559695.